ViaDerma, Inc. Logo

ViaDerma, Inc.

VDRM

(2.2)
Stock Price

0,01 USD

4.1% ROA

-248% ROE

118.99x PER

Market Cap.

6.168.550,00 USD

153.22% DER

0% Yield

-37.83% NPM

ViaDerma, Inc. Stock Analysis

ViaDerma, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ViaDerma, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (23%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 ROE

The stock's ROE falls within an average range (8.52%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (6.27%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-4), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

ViaDerma, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ViaDerma, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

ViaDerma, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ViaDerma, Inc. Revenue
Year Revenue Growth
2007 17.958
2008 15.904 -12.91%
2009 25.262.562 99.94%
2010 26.828.833 5.84%
2011 19.007.639 -41.15%
2012 23.269.424 18.31%
2015 191.777 -12033.58%
2016 251.981 23.89%
2017 44.691 -463.83%
2018 45.973 2.79%
2019 10.395 -342.26%
2020 11.468 9.36%
2021 514.007 97.77%
2022 540.648 4.93%
2023 600.498 9.97%
2024 601.960 0.24%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ViaDerma, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ViaDerma, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 0
2008 0 0%
2009 3.222.178 100%
2010 1.137.096 -183.37%
2011 664.650 -71.08%
2012 759.116 12.44%
2015 17 -4744375%
2016 60 73.33%
2017 356 83.15%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ViaDerma, Inc. EBITDA
Year EBITDA Growth
2007 -139.864
2008 -17.140 -716.01%
2009 7.048.034 100.24%
2010 9.326.928 24.43%
2011 6.858.535 -35.99%
2012 9.380.736 26.89%
2015 94.710 -9804.69%
2016 128.410 26.24%
2017 -592.440 121.67%
2018 -709.990 16.56%
2019 -337.560 -110.33%
2020 -70.470 -379.01%
2021 328.320 121.46%
2022 245.390 -33.8%
2023 185.470 -32.31%
2024 423.080 56.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ViaDerma, Inc. Gross Profit
Year Gross Profit Growth
2007 17.958
2008 13.930 -28.92%
2009 10.980.502 99.87%
2010 10.146.841 -8.22%
2011 5.661.336 -79.23%
2012 7.765.772 27.1%
2015 180.827 -4194.59%
2016 240.280 24.74%
2017 36.665 -555.34%
2018 24.497 -49.67%
2019 9.858 -148.5%
2020 10.831 8.98%
2021 511.335 97.88%
2022 540.451 5.39%
2023 600.302 9.97%
2024 601.764 0.24%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ViaDerma, Inc. Net Profit
Year Net Profit Growth
2007 -141.484
2008 -19.084 -641.37%
2009 4.094.623 100.47%
2010 4.506.926 9.15%
2011 2.672.785 -68.62%
2012 3.819.304 30.02%
2015 27.121 -13982.46%
2016 -121.806 122.27%
2017 -1.518.384 91.98%
2018 -2.998.022 49.35%
2019 -599.270 -400.28%
2020 -431.673 -38.82%
2021 -994.178 56.58%
2022 590.674 268.31%
2023 4.097 -14317.23%
2024 350.460 98.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ViaDerma, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 -12
2008 0 0%
2009 31 100%
2010 33 9.09%
2011 20 -73.68%
2012 28 32.14%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ViaDerma, Inc. Free Cashflow
Year Free Cashflow Growth
2007 -21.664
2008 1.691 1381.14%
2009 -2.214.347 100.08%
2010 650.558 440.38%
2011 -3.377.882 119.26%
2012 36.883 9258.37%
2015 -11.189 429.64%
2016 -12.064 7.25%
2017 -167.361 92.79%
2018 -83.901 -99.47%
2019 -15.116 -455.05%
2020 -8.769 -72.38%
2021 1.426 714.94%
2022 -1.493 195.51%
2023 175 958.05%
2024 367.658 99.95%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ViaDerma, Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 -21.664
2008 1.691 1381.14%
2009 3.308.043 99.95%
2010 7.777.054 57.46%
2011 6.054.149 -28.46%
2012 2.032.539 -197.86%
2015 -11.189 18265.51%
2016 -12.064 7.25%
2017 -167.361 92.79%
2018 -83.901 -99.47%
2019 -15.116 -455.05%
2020 -8.769 -72.38%
2021 1.426 714.94%
2022 -1.493 195.51%
2023 175 958.05%
2024 367.658 99.95%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ViaDerma, Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 0
2008 0 0%
2009 5.522.390 100%
2010 7.126.496 22.51%
2011 9.432.031 24.44%
2012 1.995.656 -372.63%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ViaDerma, Inc. Equity
Year Equity Growth
2007 9.044
2008 -12.591 171.83%
2009 23.453.634 100.05%
2010 29.207.280 19.7%
2011 33.559.749 12.97%
2012 35.097.882 4.38%
2015 -553.903 6436.47%
2016 -286.808 -93.13%
2017 -1.051.094 72.71%
2018 -2.720.301 61.36%
2019 -2.995.858 9.2%
2020 -2.187.804 -36.93%
2021 -2.435.180 10.16%
2022 -1.844.506 -32.02%
2023 123.150 1597.77%
2024 210.765 41.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ViaDerma, Inc. Assets
Year Assets Growth
2007 9.044
2008 6.239 -44.96%
2009 30.049.439 99.98%
2010 36.074.032 16.7%
2011 42.645.374 15.41%
2012 45.832.457 6.95%
2015 175.858 -25962.2%
2016 386.504 54.5%
2017 426.560 9.39%
2018 56.415 -656.11%
2019 69.225 18.5%
2020 123.033 43.73%
2021 275.021 55.26%
2022 713.979 61.48%
2023 1.280.834 44.26%
2024 1.263.933 -1.34%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ViaDerma, Inc. Liabilities
Year Liabilities Growth
2007 0
2008 18.830 100%
2009 6.595.805 99.71%
2010 6.866.752 3.95%
2011 9.085.625 24.42%
2012 10.734.575 15.36%
2015 729.761 -1370.97%
2016 673.312 -8.38%
2017 1.477.654 54.43%
2018 2.776.716 46.78%
2019 3.065.083 9.41%
2020 2.310.837 -32.64%
2021 2.710.201 14.74%
2022 2.558.485 -5.93%
2023 1.157.684 -121%
2024 1.053.168 -9.92%

ViaDerma, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
118.99x
Price To Sales Ratio
10.27x
POCF Ratio
16.76
PFCF Ratio
16.76
Price to Book Ratio
29.27
EV to Sales
10.17
EV Over EBITDA
26.08
EV to Operating CashFlow
16.61
EV to FreeCashFlow
16.61
Earnings Yield
0.01
FreeCashFlow Yield
0.06
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
0
Income Quality
7.1
ROE
1.04
Return On Assets
-0.06
Return On Capital Employed
1.01
Net Income per EBT
1
EBT Per Ebit
1.56
Ebit per Revenue
-0.24
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
1
Operating Profit Margin
-0.24
Pretax Profit Margin
-0.38
Net Profit Margin
-0.38

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.44
Return on Tangible Assets
0.04
Days Sales Outstanding
537.06
Days Payables Outstanding
21788.27
Days of Inventory on Hand
0
Receivables Turnover
0.68
Payables Turnover
0.02
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
1.53
Debt to Assets
0.26
Net Debt to EBITDA
-0.23
Current Ratio
1.2
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
208847
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ViaDerma, Inc. Dividends
Year Dividends Growth

ViaDerma, Inc. Profile

About ViaDerma, Inc.

ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. It focuses on developing and marketing pharmaceutical products, as well as licensing its technology to companies in the pharmaceutical industry in various therapeutic areas. The company's lead product is Vitastem, a tetracycline-based topical antibiotic used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. It is also developing products in various fields of use, including topical antibiotics, toenail antifungal drugs, diabetic amputations, global acne, psoriasis, and eczema, as well as burns, anti-aging/wrinkle remover creams, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California.

CEO
Dr. Christopher A Otiko
Employee
0
Address
4640 Admiralty Way
Marina del Rey, 90292

ViaDerma, Inc. Executives & BODs

ViaDerma, Inc. Executives & BODs
# Name Age
1 Mr. Qing Hua Lin
Chief Financial Officer and Director
70
2 Dr. Christopher A Otiko
Founder, Chief Executive Officer and President
70
3 Dr. Andrew Berman M.D., MPH
Medical Director and Member of Advisory Board
70
4 Mr. Zhang Xie
Corporate Secretary and Director
70
5 Mr. Baotang Zhao
Chief Sales Officer
70

ViaDerma, Inc. Competitors